Christine Wang's Innovative Fruit Peel-Based Water Purification System that Removes Toxic Heavy Metals Featured in XYZ Media's 'Next Generation of Innovators'
Her project, 'Utilizing Fruit Peel Waste for Contaminated Water Treatment,' combines scientific ingenuity with sustainability, offering a nearly zero-cost, scalable solution. Christine's work uses the natural filtration capabilities of compounds found in fruit peels—like lignin, cellulose, and pectin—to remove toxic heavy metals such as silver, nickel, chromium, cadmium, lead, copper, iron, and zinc. Her innovation is not only validated through home-based trials but has been professionally confirmed by a certified laboratory using atomic absorption spectroscopy, showing over 1000× reduction in heavy metal levels, exceeding U.S. EPA standards by more than 100-fold.
'I have always believed that safe drinking water should be a basic guarantee, especially here in California,' Christine said. 'After learning that even schools and businesses in my own community were failing to meet heavy metal drinking water safety standards, I realized how fragile that assumption is. At the same time, I became aware of the amount of fruit waste generated from our everyday lives. Observing the considerable amount of natural materials that are thrown away made me wonder whether these underutilized resources could provide answers to problems that we frequently assume call for costly and complex technologies.'
The originality of Christine's method lies not only in her use of natural compound materials and household items, but also in the pre-activation process that prepares the filter for more effective water treatment. After multiple filter designs and tests, she created an optimal structure that achieves fast flow rate, minimal powder use, and effective filtration.
'One of the greatest challenges I faced was finding a balance between scientific efficacy and practicality for my filters in removing heavy metals. While my initial filtration designs were highly effective in filtration, they were unsuitable for real-world applications due to the length of filtration time. After more than six rounds of development, I devised a filter creation method that dramatically reduced filtration time to just one minute while maintaining strong performance. Another challenge was verifying my results with professional accuracy. I reached out to a certified laboratory to test my filters using atomic absorption spectroscopy, and the results confirmed that my filters reduced heavy metal concentrations well below EPA standards. These challenges pushed me to refine my designs and think more critically about how my innovation could uphold both scientific rigor and real-world practicality.'
'In my ideal world everyone would have access to safe drinking water without regard to geography or socioeconomic status,' Christine said. 'In future research, I want to expand my current roster of successful fruit peel wastes to determine the best means of mass production and identify an effective distribution system to push for a more comprehensive change in the way we think about waste and resource accessibility.'
Jordan Hayes, Director of Communications at XYZ Media, commended Christine's scientific precision and purpose-driven research: 'Christine's work shows just how powerful everyday materials can be in the hands of a creative mind. Her ability to design, test, and fine-tune a low-cost water purification system is a perfect example of how innovation and empathy can go hand in hand. She truly embodies what it means to be a 'Next Generation Innovator.''
Through this series, XYZ Media continues its commitment to amplifying youth-led breakthroughs that merge environmental responsibility with scalable science, making clean water not just a hope—but a possibility grounded in research.
About XYZ Media:
Founded in 2018, XYZ Media is a media and marketing company that stands at the forefront of integrating educational initiatives with technological innovation, driving market trends, and shaping the digital landscape. XYZ Media is dedicated to spotlighting the achievements of tomorrow's leaders driving change. With a keen focus on educational excellence and digital innovation, XYZ Media fosters a community where young minds are encouraged to challenge the status quo and develop solutions for a better tomorrow.
To learn more information on XYZ Media's 'Next Generation of Innovators' series, please contact:
Jordan HayesDirector of Communicationspr@xyzmediaco.comXYZ Media21606 Devonshire Street, Los Angeles, CA 91311www.xyzmediaco.com
Disclaimer: This content is provided by XYZ Media. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own risk.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c8045133-8ef0-4c01-9dcc-a844cbee96f9
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Mars and Pairwise Collaborate to Accelerate Cacao Research and Development
Durham, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mars, Incorporated has licensed Pairwise's Fulcrum® gene editing tools for cacao research and development. This licensing agreement grants Mars access to Pairwise's CRISPR tools, including the SHARC™ enzyme. The Pairwise Fulcrum platform encompasses gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential. This capability significantly accelerates the development of impactful crop traits compared to traditional breeding methods, allowing for the activation or deactivation of characteristics and fine-tuning traits, much like adjusting a dimmer switch to achieve optimal results. Mars aims to develop this advanced plant breeding technology to improve cacao production and effectively tackle agricultural challenges. The ultimate goal is to help address the pressures cacao faces globally from climate variability, plant diseases and environmental stresses. This strategic initiative underscores the potential of this technology to drive meaningful advancements in agriculture. "At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains," said Carl Jones, Plant Sciences Director at Mars. "Our focus is to transparently and responsibly conduct CRISPR research in plant science that helps crops better adapt to climate challenges, disease pressures and resource constraints." "We're pleased to provide Mars with access to our Fulcrum platform for their cacao research and development initiatives," said Ian Miller, Chief Operating Officer at Pairwise. "Plant breeding innovation has the potential to help address important agricultural challenges, and we look forward to supporting Mars' research goals." The Pairwise Fulcrum platform includes gene editing tools, enzymes and trait libraries, enabling precise changes that unlock the plant's inherent potential to greatly accelerate the development of impactful crop traits compared to traditional breeding methods.### About Pairwise Pairwise is agriculture's gene editing powerhouse, building a healthier world through partnership and plant innovation. Co-founded by the inventors of CRISPR, our Fulcrum® Platform accelerates the development of climate-resilient, nutritious, and sustainable crops. As trusted partners to global industry leaders and nonprofit institutions, we help breeders move faster while transforming food and agriculture for farmers, consumers, and the planet. Founded in 2017 and based in Durham, NC, Pairwise is committed to delivering innovation that makes food easier to grow and better to eat. For more information, visit CONTACT: Communications Pairwise communications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
a day ago
- Business Upturn
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases. This is believed to be the result of targeted accumulation in the liver and other organs. These findings were highlighted in a poster titled ' Liposomal Annamycin (L-ANN) Efficacy Against Primary and Metastatic Liver Cancers , ' presented by Dr. Waldemar Priebe, Lead Author and Chairman of the Scientific Advisory Board at Moleculin at the recently held Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center. Key Highlights Targeted Accumulation in Organs: The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. Efficacy in Orthotopic Hepatocellular Carcinoma (HCC) Models: Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Potent Impact on Colorectal Liver Metastasis: In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. Promising Results in Pancreatic Cancer Liver Metastasis: Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Favorable Safety Profile: Consistent with previous preclinical and clinical findings, Annamycin continued to show low or no cardiotoxicity, a significant advantage over traditional anthracyclines like doxorubicin, which are often limited by dose-dependent cardiac side effects. This safety profile was previously observed in clinical trials, where 32 out of 42 subjects reviewed received more than the FDA-established lifetime maximum allowable level of anthracycline without evidence of cardiotoxicity. 'We are incredibly encouraged by these preclinical results, which further validate Annamycin's potential as a powerful and differentiated therapeutic agent for liver cancers,' said Dr. Priebe. 'The ability of Annamycin to concentrate effectively in the liver, combined with its demonstrated efficacy across multiple aggressive liver cancer models and its favorable cardiotoxicity profile, positions it as a highly promising candidate for patients facing these devastating diseases. We believe these data provide a strong foundation for advancing Annamycin in clinical development for these indications, offering new hope where treatment options are often limited.' Walter Klemp, Chairman and CEO of Moleculin, added, 'We continue to be strongly encouraged by the potential of Annamycin. Beyond our preliminary programs in AML and soft tissue sarcoma lung metastases (STS lung mets), we continue to advance and develop Annamycin through multiple investigator-initiated studies to further unlock its potential as a treatment option for many other types of cancers. We believe this preclinical data highlights that potential and provides additional validation of its unique pharmacological profile and importantly showcases the opportunity for its use across a wide range of cancers.' Moleculin's novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of AML and STS lung mets. For more information, please visit About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the whether the preclinical results described above are able to be reproduced in clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected]


Business Upturn
a day ago
- Business Upturn
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its second quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and a live audio webcast at 8 a.m. ET, to discuss the second quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast. Advertisement Conference Call Dial-In & Webcast Information: The live and archived webcast will also be available in the Investors section of the Company's website at About BiomX BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ('BacteriOphage Lead to Treatment') platform to customize phage compositions against these targets. For more information, please visit the content of which does not form a part of this press release. BiomX, Inc. Ben Cohen [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.